The risk evaluation and mitigation strategy program for clozapine allows for patients to receive clozapine—even in the setting of moderate to severe neutropenia—if the benefit to psychiatric treatment outweighs the risk of recurrent neutropenia. However, literature that can guide appropriate treatment for such patients is limited. A recently published case report suggests that using filgrastim to control leukopenia and neutropenia could allow patients to continue to receive clozapine without interruption.
For patients with treatment-resistant schizophrenia, clozapine is a key antipsychotic. However, because clozapine is associated with hematological abnormalities, including neutropenia and leukopenia, patients must sometimes discontinue treatment. Sudden withdrawal of clozapine is linked with serious outcomes, however, including an increased risk of suicide.
The risk evaluation and mitigation strategy program for clozapine allows for patients to receive clozapine—even in the setting of moderate to severe neutropenia—if the benefit to psychiatric treatment outweighs the risk of recurrent neutropenia. However, literature that can guide appropriate treatment for such patients is limited.
A recently published case report suggests that using filgrastim to control leukopenia and neutropenia could allow patients to continue to receive clozapine without interruption. Published in The Mental Health Clinician, the report describes a 55-year-old male patient with chronic paranoid schizophrenia.
Learn more about filgrastim biosimilars.
The patient had achieved significant clinical improvement with clozapine treatment, and he attained functional independence without hospitalization. He was able to receive 20 years of clozapine therapy before he developed leukopenia, after which clozapine was withdrawn, precipitating a rapid worsening of his schizophrenia symptoms. Over the following 2 years, the patient tried, and had an inadequate response to, 7 other medications.
Because the patient’s symptoms were worsening, a retrial of clozapine was deemed necessary. However, 2 months after discharge from the hospital following psychiatric improvement with clozapine therapy, moderate leukopenia and mild neutropenia recurred, and his clozapine was once again held.
The patient was then treated with 5 daily doses of subcutaneous filgrastim (300 mcg/mL), and his white blood cells and absolute neutrophil count recovered within 4 days, allowing him to restart his clozapine. An interdisciplinary team determined that the patient could receive uninterrupted clozapine therapy with filgrastim as needed.
The patient had 1 period of leukopenia and neutropenia that necessitated interruption of clozapine, and his filgrastim was eventually replaced with a different colony-stimulating factor therapy (sargramostim) because of a formulary change, but over the past 3 years of receiving neutropenia treatment, his schizophrenia symptoms have been well controlled, and his clozapine use has been uninterrupted. The patient continues to have his white blood cells and absolute neutrophil count monitored weekly.
The authors of the case report conclude that filgrastim or sargramostim provide a potential alternative to clozapine discontinuation in the case of neutropenia for patients who have been clinically stable on their therapy.
Reference
Kars A, Lister J. Utilization of G-CSF and GM-CSF as an alternative to discontinuation in clozapine-induced neutropenia or leukopenia: a case report and discussion. Ment Health Clin. 2018;8(5):250-255. doi: 10.9740/mhc.2018.09.250.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.